drugset / Trial / NCT06680544

Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections

NCT06680544

Phase 2 Not yet recruiting 120 enrolled Sheikh Zayed Medical College
RandomizedParallel-groupOpen-labelTreatment

Summary

Treatment of dermatophyte infection in our country (Pakistan) is becoming difficult due to the developing resistance to traditional antifungal agents. Assessing the effectiveness ,feasibility and standard dosage of a newer antifungal drug like voriconazole is the need of the hour in resistant cases of dermatophyte infection.

Timeline

Start
2024-11-15
Primary completion
2025-03-01
Completion
2025-03-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Voriconazole Small molecule 200 mg Oral

Indications